Gregory Fiore - 01 Aug 2022 Form 4 Insider Report for Brooklyn ImmunoTherapeutics, Inc. (ERNA)

Reporting relationship: Director
Issuer ticker: ERNA
Reported as of: 01 Aug 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Aug 2022, 20:01:27 UTC
Prior SEC filing: 07 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Gregory Fiore

Key filing fact

Gregory Fiore filed Form 4 for Brooklyn ImmunoTherapeutics, Inc. (ERNA) on 03 Aug 2022.

Key facts

This page summarizes Gregory Fiore's Form 4 filing for Brooklyn ImmunoTherapeutics, Inc. (ERNA).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 03 Aug 2022, 20:01.

Change

Previous filing in this sequence was filed on 07 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ERNA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +95,100
Change %
Price: $0.000000
Shares after: 95,100
Date: 01 Aug 2022
Ownership: Direct
Underlying class: Common Stock, par value $0.005 per share
Underlying amount: 95,100
Exercise price: $0.4900
Footnotes: F1

ERNA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +165,800
Change %
Price: $0.000000
Shares after: 165,800
Date: 01 Aug 2022
Ownership: Direct
Underlying class: Common Stock, par value $0.005 per share
Underlying amount: 165,800
Exercise price: $0.4900
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The stock option vests and becomes exercisable over one year (subject to continued service), with 25% of the shares vesting every three months from the grant date.

Footnote F2

The stock option vests and becomes exercisable over two years (subject to continued service), with 1/3 of the shares vesting on the grant date and the remaining shares vesting in 24 substantially equal monthly installments thereafter.